A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

Part of paid clinical trials in Aurora, Colorado.

Sponsor
Novo Nordisk A/S
Study ID
NCT07220564
Phase
PHASE1
Status
Recruiting

Conditions

  • Haemophilia A

Eligibility Criteria

Sex
MALE
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • NNC0442-0344 A — DRUG
    NNC0442-0344 A will be administered orally.

Study Details

This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.

Key Dates

Start date
Oct 23, 2025
Status verified
Apr 2026
Primary completion
Feb 5, 2027
Completion
Feb 5, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    Participants will receive oral dose of NNC0442-0344 A.
  • Experimental: Cohort 2
    Participants will receive oral dose of NNC0442-0344 A.
  • Experimental: Cohort 3
    Participants will receive oral dose of NNC0442-0344 A.

Primary Outcome Measure

Number of treatment emergent adverse events [ Time Frame: From time of dosing (Day 1) to end of follow-up (Day 46) ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
UC Denver Hemoph & Thrombo CtrAuroraColorado80045-
Indiana Hemophilia-Thromb CtrIndianapolisIndiana46260-
University of Iowa_Iowa CityIowa CityIowa52242-
Penn State MS Hershey Med CtrHersheyPennsylvania17033-2360-
St Christopher Hosp for ChildPhiladelphiaPennsylvania19134-

Find similar trials in Aurora, CO

Related Studies